All News

AAO-HNS Continues Advocacy on Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis (2/5/2020)

AAO-HNS Continues Advocacy on Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis (2/5/2020)

On February 5, the AAO-HNS sent comments to Blue Cross Blue Shield’s Federal Employee Program (BCBS FEP) opposing their medical policy designating balloon ostial dilation (BSOD) as experimental/investigational. The comment letter highlights the AAO-HNS Position Statement and Clinical Consensus Statement on BSOD, as well as provides extensive literature support demonstrating the procedure is consistent with the standard of care.

No External Use or Transfer (Including AI-Based Technologies): The materials and content on this website are provided for personal, non-commercial transitory viewing only. You are prohibited from copying or transferring any materials or content accessed through this website into applications, software, bots, or websites which may allow third parties to retain or use the content, including but not limited to those using artificial intelligence-based technologies or infrastructure. Please see the Terms of Use for more information.